Meta-analysis of some results of clinical trials on sulodexide therapy in peripheral occlusive arterial disease

Journal of International Medical Research

Volumn 24, Issue 5, 1996, Pages 389-406

  Gaddi, A ^a   Galetti, C ^a   Illuminati, B ^a   Nascetti, S ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Claudication; Diabetes; Fibrinogen; Glycosaminoglycans; Meta analysis; Peripheral occlusive arterial disease; Sulodexide; Viscosity

Indexed keywords

FIBRINOGEN; GLYCOSAMINOGLYCAN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; SULODEXIDE; TRIACYLGLYCEROL;

ARTICLE; BLOOD VISCOSITY; CLAUDICATION; CLINICAL TRIAL; DIABETES MELLITUS; DISEASE COURSE; DRUG COST; DRUG TOLERABILITY; HUMAN; META ANALYSIS; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PLASMA VISCOSITY; SERUM;

EID: 0029832071     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/030006059602400501     Document Type: Article

References (84)

1. Keen H: Macrovascular disease in diabetes mellitus. In: Diabetic complications: early diagnosis and treatment (Andreani D, Crepaldi, G, Di Mauro U, et al eds). McGraw, NY, 1987; pp 3-12.
2. O'Brien B, Rushly J: Outcome assessment in cardiovascular cost/benefit studies. Am Heart J 1990; 119: 740-747.
3. Ernst E, Matrai A: Intermittent claudication, exercise and blood rheology. Circulation 1987; 76: 1110-1116.
4. Clifford PC, Davies PW, Hayne JA, et al: Intermittent claudication: is a supervised exercise class worthwhile? BMJ 1980; 280: 1503-1507.
5. Genest J Jr, Cohn JS: Clustering of cardiovascular risk factors: targeting high-risk individuals. Am J Cardiol 1955; 13: 8A-20A.
6. McAllister FF: The fate of patients with intermittent claudication managed non-operatively. Am J Surg 1976; 132: 593-598.
7. Lindagarde F, Bjorkman H, Adielsson G, et al (for the Scandinavian Study Group): Conservative drug treatment in patients with moderately severe chronic occlusive peripheral arterial disease. Circulation 1989; 80: 1549-1556.
8. Fowker FG: Fibrinogen and peripheral arterial disease. Eur Heart J 1995; 16 (Suppl. A): 36-40.
9. Ernst E: Plasma fibrinogen: an independent cardiovascular risk factor. J Intern Med 1990; 227: 365-372.
10. Busutti L, Breccia A: Pharmacokinetics of sulodexide after single oral administration in man. Eur J Clin Res 1991; 1: 25-36.
11. Oriente P, Spanò A, Postiglione L, et al: Variazioni della composizione delle lipoproteine del siero e dell'attività lipoproteinlipasica indotte dal glucoronil-glucosaminoglicano solfato: confronto con l'eparina sodica. G Arterioscl 1980; 5: 159-166.
12. Barbanti M, Aldini R, Barbara L, et al: Effect of sulodexide, a heparin-like compound on VLDL-triglyceride in the perfused rat liver. IRCS Med Sci 1985; 13: 1147-1148.
13. Tiozzo R, Cingi MR, Pietrangelo A, et al: Effect of heparin-like compounds on the in vitro proliferation and protein synthesis of various cell types. Arzneimittelforschung 1989; 39: 15-20.
14. Andriuoli G, Mastacchi R, Barbanti M: Antithrombotic activity of a glycosaminoglycan (sulodexide) in rats. Thromb Res 1984; 34: 81-86.
15. Barbanti M, Guizzardi S, Calanni F, et al: Antithrombotic and thrombolytic activity of sulodexide in rats. Int J Clin Lab Res 1992; 22: 179-184.
16. Palazzini E, Procida C: Effect of some mucopolysaccharides on activated factor X. Biochem Pharmacol 1975; 27: 608-610.
17. Mauro M, Ferraro G, Palmieri G: Profibrinolytic and antithrombotic effects of sulodexide oral administration: a double-blind, cross-over, placebo-controlled study. Curr Ther Res 1992; 51: 342-350.
18. Fiore G, Baraldi A, Gambarotta GC, et al: Inhibition of plasminogen activator (PAI-1) by sulodexide in post-thrombophlebitic patients. J Drug Dev 1991; 3(4): 173-178.
19. Condorelli M, Chiariello M, Dagianti A, et al: IPO-V2: prospective, multicenter, randomized, comparative clinical investigation of the effects of sulodexide in preventing cardiovascular accidents in the first year after acute myocardial infarction. J Am Coll Cardiol 1994; 23: 27-34.
20. Begg C, Berlin J: Publication bias: a problem in interpreting medical data. J R Stat Soc A 1988; 151: 419-463.
21. Bartolo M, Antignani PL, Eleuteri P: Experiences with sulodexide in the arterial peripheral diseases. Curr Ther Res 1984; 36: 979-988.
22. Bonalumi F, Sarcina A, Bonadeo P, et al: A randomized protocol for the management of chronic arterial diseases by means of sulodexide. Eur Rev Med Pharmacol Sci 1986; 8: 123-129.
23. Bonanno G, Bonaccorso R, Dell'Ali C, et al: Sulodexide in the treatment of atherosclerosis: a controlled clinical trial. Acta Ther 1985; 11: 87-98.
24. Borreani B, Brizio L, Cianfanelli G, et al: Valutazione dell'attività del sulodexide nell'arteriopatia cronica periferica scleroateromatosa. Gazz Med Ital-Arch Sci Med 1993; 152: 21-24.
25. Calabrò A, Rossi A, Baiocchi AM, et al: Effetto del sulodexide su alcuni parametri emoreologici in un gruppo di pazienti con vasculopatia arteriosclerotica periferica. La Ricerca Clin Lab 1985; 15 (suppl 1): 455-463.
26. Caramelli L, Mirchioni R, Carini A: Effectiveness of short-term sulodexide treatment on peripheral vascular disease clinical manifestations. Eur Rev Med Pharmacol Sci 1988; 10: 55-58.
27. Castelluccio A, Bologna E: Effect of sulodexide on blood viscosity in patients with peripheral vascular disease. Curr Med Res Opin 1991; 12: 325-331.
28. Ciuffetti G, Mercuri M, Susta A, et al: Effects of 3-glucosaminoglycan sulfate on hemorrheologic parameters in hyperlipidemic peripheral vascular disease (PVD) patients: a preliminary double-blind crossover study. Angiology 1989; 40: 255 -259.
29. Corsi C, Bocci L, Cipriani C, et al: The effectiveness of glycosaminoglycans in peripheral vascular disease therapy: a clinical and experimental trial. J Int Med Res 1985; 13: 40-47.
30. Cospite M, Milio G, Ferrara F, et al: Double-blind study of the pharmacological effects of sulodexide in patients with multiple atherosclerotic vascular disease. Eur Rev Med Pharmacol Sci 1985; 7: 97-106.
31. Crepaldi G, Fellin R, Calabrò A, et al: Double-blind multicenter trial on a new medium molecular weight glycosaminoglycan. Current therapeutic effects and perspectives for clinical use. Atherosclerosis 1990; 81: 233-243.
32. Di Stefano F, Patanè S, Vinci M, et al: Medical treatment of atherosclerosis: controlled clinical trial with new glycosaminoglycan sulodexide. Eur Rev Med Pharmacol Sci 1984; 6: 525-532.
33. Lunetta M, Salanitri T: Lowering of plasma viscosity by the oral administration of the glycosaminoglycan sulodexide in patients with peripheral vascular disease. J Int Med Res 1992; 20: 45-53.
34. Marzola M, Donati D, Indelli M, et al: Il sulodexide nel trattamento del vasculopatico iperlipidemico: studio in doppio cieco. Eur Rev Med Pharmacol Sci 1985; 7: 273-279.
35. Palmieri G, Perego M, Nazzari M, et al: Valutazione di un sulfomucopolisaccaride (3GS) net trattamento delle iperlipoproteinemie. Clin Ter 1982; 101: 603-614.
36. Palmieri G, Nazzari M, Ambrosi G, et al: Sulodexide in the treatment of peripheral arterial disease. Clin Trials J 1984; 21: 411-427.
37. Perego M, Nazzari M, Palmieri G: 3-Glucosamin-Glicano-Solfato per via parenterale in pazienti aterosclerotici iperlipidemici. G Arterioscl 1981; 6: 289-298.
38. Perego M, Palmieri G, Nazzari M: Effects of oral and parenteral 3GS administration on blood lipids and haemostatic parameters in atherosclerotic hyperlipidaemic patients. In: Atherosclerosis: etiopathogenesis, clinical evaluation and therapy (Lenzi S, Descovich GC, eds) Compositori, Bologna, 1982, pp 457-463.
39. Pisano L, Moronesi F, Falco F, et al: The use of sulodexide in the treatment of peripheral vasculopathy accompanying metabolic diseases. Controlled study in hyperlipidemic and diabetic subjects. Thromb Res 1986; 41: 23-31.
40. Oikin I. Statistical and theoretical considerations in meta-analysis. J Clin Epidemiol 1995; 48:133-146.
41. Science Citation Index, Journal Citation Reports (Microfiche Edition), Inst. Scient Inform. 1992.
42. Slacks HS, Berrier J, Reitman D, et al: Meta-analysis of randomized controlled trials. N Engl J Med 1987; 316: 450-455.
43. Messori A, Rampazzo R, Scuffi C: In: La Metaanalisi: teoria e applicazioni (Il Pensiero Scientifico, Ed) Roma, 1994, pp 22-35.
44. Mantel N, Haenszel W: Statistical aspects of the analysis of data from retrospective studies of disease. J Nat Cancer Inst 1959; 22: 719-748.
45. Robins J, Breslow N, Greenland S: Estimators of the Mantel-Haenszel variance consistent in both sparse data and large strata limiting models. Biometrics 1986; 42: 311-323.
46. Der Simonian R, Laird N: Meta analysis in clinical trials. Control Clin Trials 1986; 7: 177-188.
47. Lau J, Antamen EM, Jimenez-Silva J, et al: Cumulative meta-analysis of therapeutic trials for myocardial infarction. N Engl J Med 1992; 327: 248-254.
48. Collins R, Yusuf S, Peto R: Overview of randomised trials on diuretics in pregnancy. BMJ 1985; 290: 17-23.
49. Klein S, Simes J, Blackburn GL: Total parenteral nutrition and cancer in clinical trials. Cancer 1986; 58: 1378-1386.
50. Bulpitt CJ: Confidence Intervals. Lancet 1987; II: 494-498.
51. Gardner MJ, Altman DJ: Confidence intervals rather than P values: estimations rather than hypothesis testing. BMJ 1986; 292: 746-750.
52. Armitage P: Statistical methods in medical research (Blackwell, ed) Oxford, 1971.
53. Statistical Graphic Package (rel. 3.0) STSC Corporation and Manugistic, Rockville, Maryland, USA, 1992; Rel. 3.1.
54. Messori A, Martini N, Scroccaro G: Calculations errors in meta-analysis. Ann Intern Med 1993; 118: 77-78.
55. Messori A, Rampazzo R: Meta-analysis of clinical trial based on censored end points: simplified theory and implementation of the statistical algorithms on microcomputer. Comput Programs Biomed 1993; 40: 261-267.
56. Breslow NE, Day NE: Statistical methods in cancer research (Vol. I). IARC Scient. Public., Lyon 1980.
57. Breslow NE, Day NE: Statistical methods in cancer research (Vol. II). The design and analysis of cohort studies. IARC Scient. Public., Lyon, 1980.
58. Allen EV, Barker NW, Hines EA: Peripheral vascular disease (Saunders WB, ed). Philadelphia, 1962.
59. National Diabetes Data Group: Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 1987; 28: 1039-1053.
60. The working group on hypertension in diabetes. Statement on hypertension in diabetes mellitus: final report. Arch Intern Med 1987; 147: 830-842.
61. WHO Committee: Classification of hyperlipidemias and hyperlipoproteinemias. Bull World Health Organ 1970; 43: 891.
62. Goldstein JL, Brown MS: Familial hypercholesterolemias. In: Metabolic basis of inherited diseases (Stanbury JB, Wyngaarden JB, Fredrickson DS, et al eds). McGraw-Hill BC, 1983; pp 675.
63. Beaumont JL, Carlson LA, Cooper RG, et al: Classification of hyperlipidemias and hyperlipoproteinemias. Bull World Health Organ 1970; 43: 891-915.
64. Sprovieri G, Lippi U, Graziani MS, et al on behalf of Commissione Nazionale Congiunta AIPAC, SIBIoC, SIMEL, CISMEL, ASFA and of Gruppo di Studio delle Malattie Dismetaboliche e dell'Aterosclerosi: Linee guida per la diagnostica di laboratorio delle dislipidemie. Biochim Clin 1995; 19: 198-205; Patol Clin 1995; 1: 42-48.
65. Sprovieri G, Lippi U, Graziani MS, et al on behalf of Commissione Nazionale Congiunta AIPAC, SIBIoC, SIMEL, CISMEL, ASFA and of Gruppo di Studio delle Malattie Dismetaboliche e dell'Aterosclerosi: Linee guida per la diagnostica di laboratorio delle dislipidemie. Biochim Clin 1995; 19: 198-205; Patol Clin 1995; 1: 42-48.
66. Wells RE, Denton R, Merrill EW: Measurement of viscosity of biological fluids by cone-plate microviscosimeter. J Lab Clin Med 1961; 57: 646-648.
67. German Society for Angiology: Guidelines for therapeutic studies in Fontaine's stages II-IV peripheral arterial occlusive disease. Vasa 1995; 24: 114-119.
68. Berenson GS, Radhakrishnamurthy B, Srinivasan SR, et al: Proteoglycans and potential mechanisms related to atherosclerosis. In: Atherosclerosis (Lee KT, ed) Ann NY Acad Sci 1985; 454: 69-76.
69. Hoover RL, Rosenberg R, Haering W, et al: Inhibition of rat arterial smooth muscle cell proliferation by heparin. Circ Res 1980; 47: 578-583.
70. Lindahl U, Hook M: Glycosaminoglycans and their binding to biological macromolecules. Ann Rev Biochem 1978; 47: 385-417.
71. Di Minno G, Mancini M: Measuring plasma fibrinogen to predict stroke and myocardial infarction. Arteriosclerosis 1990; 10: 1-7.
72. Di Perri T, Laghi Pasini F, Guerrini M, et al: Action of intravenous glucosamineglycan-sulphate on lipid blood components and blood viscosity in patients with acute regional vasculopathies. G Arterioscl 1978; 3: 41-46.
73. Jung F, Pindur G, Kieewetter H: Plasma viscosity dependence on protein and lipoprotein. Results of the Aachen Study. Clin Hemorrheol 1992; 12: 557-571.
74. Messa GL, La Placa G, Puccetti L, et al: Pharmacodynamic effects of sulodexide on profibrinolytic and haemorrheological patterns. Clin Drug Invest 1995; 10: 165-171.
75. Palazzini E, Verardi S: Effect of naturally occurring mucopolysaccharide, 3-GS, on coagulative parameters in patients under chronic haemodialytic treatment. Curr Ther Res 1981; 29: 678-684.
76. Palmieri G, Ambrosi G, Nazzari M, et al: The influence of sulodexide on some coagulation parameters. A pharmacokinetic study. Clot Hemat Mal 1985; II: 7-13.
77. Lowe GDO, Wood DA, Douglas JT, et al: Relationships of plasma viscosity, coagulation and fibrinolysis to coronary risk factors and angina. Thromb Haemost 1991; 65: 339-343.
78. Dormandy JA, Murray GD: The fate of the claudicant. A prospective study of 1969 claudicants. Eur J Vasc Surg 1991; 5: 131-133.
79. Banerjee AK, Pearson J, Gilliland EL, et al: A six-year prospective study of fibrinogen and other risk factors associated with mortality in stable claudicants. Thromb Haemost 1992; 68: 261-263.
80. Pyorala K, Laakso M, Uusitura M: Diabetes and atherosclerosis: an epidemiological view. Diabetes Metab Rev 1987; 3: 463-524.
81. Jarrett RJ, Keen H, Grabauskas AV: The WHO multinational study of vascular disease in diabetics: I. General description. Diabetes Care 1979; 2: 175-186.
82. Rudofsky G, van-Laak C: Treatment cost of PAOD in Germany: a comparison of cost and efficacy. J Cardiovasc Pharmac 1994; 23: 22-25.
83. Lebrun T, Selke B, Sailly JC, et al: The introduction of economic criteria into the management of arterial disease: an illustration with regard to the socioeconomic consequences of POAD of the lower limbs. J Cardiovasc Pharmac 1994; 23: 17-21.
84. Stern PH: Occlusive vascular disease of lower limbs: diagnosis, amputation surgery and rehabilitation. Am J Phys Med Rehab 1988; 67: 145-154.